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53 is a well known tumor suppressor. We show
that p53 also regulates osteoblast differentiation,
bone formation, and osteoblast-dependent osteo-
clast differentiation. Indeed, 
 
p53
 
 
 
/
 
 
 
 mice display a high
bone mass phenotype, and 
 
p53
 
 
 
/
 
 
 
 osteoblasts show ac-
celerated differentiation, secondary to an increase in
expression of the osteoblast differentiation factor osterix,
as a result. Reporter assays indicate that p53 represses
osterix transcription by the minimal promoter in a DNA-
binding–independent manner. In addition, 
 
p53
 
 
 
/
 
 
 
 osteo-
p
 
blasts have an enhanced ability to favor osteoclast differ-
entiation, in association with an increase in expression of
macrophage-colony stimulating factor, which is under the
control of osterix. Furthermore, inactivating p53 is sufﬁ-
cient to rescue the osteoblast differentiation defects ob-
served in mice lacking c-Abl, a p53-interacting protein.
Thus, these results identify p53 as a novel regulator
of osteoblast differentiation, osteoblast-dependent osteo-
clastogenesis, and bone remodeling.
 
Introduction
 
The major role of p53 is to promote cell cycle arrest, pro-
grammed cell death, and cell senescence, and it is mutated in
more than half of the primary human tumors (Ko and Prives,
1996; Vogelstein et al., 2000). p53 executes its function mainly
by activating the transcription of target genes involved in these
cellular events, in which the binding of p53 to a specific DNA
sequence is necessary (Giaccia and Kastan, 1998; Oren, 1999).
p53 can also act as a transcription repressor (Yu et al., 1999). In
some cases, the repression is independent of DNA binding (Ag-
off et al., 1993; Zhai and Comai, 2000; Crighton et al., 2003;
Rocha et al., 2003). p53 can be brought to the promoter regions
of these genes through other DNA-binding proteins, such as the
CAAT-binding factor (Zhai and Comai, 2000), where p53 may
interfere with the assembly of the transcription–initiation com-
plex (Zhai and Comai, 2000) or recruit transcription repressors
like histone deacetylase (Murphy et al., 1999; Rocha et al.,
2003). Hence, p53 can repress gene expression using complex
and diverse mechanisms, most of which are not well under-
stood. In addition, the biological significance of p53-mediated
repression remains unclear (Ho and Benchimol, 2003).
p53 has also been implicated in cell differentiation and
mouse development, although initial studies of 
 
p53
 
 
 
/
 
 
 
 mice did
not reveal any developmental abnormalities (Donehower et al.,
1992; Almog and Rotter, 1997; Choi and Donehower, 1999).
It has been reported that a small portion of homozygous em-
bryos displayed a neural tube closure defect called exencephaly
and that 
 
p53
 
 
 
/
 
 
 
 embryos were more susceptible to teratological
reagents (Sah et al., 1995; Hall and Lane, 1997), yet, the
molecular mechanisms through which p53 regulates cell differ-
entiation and mouse development remain largely unknown.
We have previously established that the nonreceptor ty-
rosine kinase c-Abl plays a positive role in murine osteoblast
differentiation and bone development (Li et al., 2000). Given
the functional relationship between c-Abl and p53, we decided
to study the role of p53 in osteoblast differentiation and bone
remodeling. Osteoblast is a cell of mesenchymal origin that is
responsible for bone formation and can support osteoclast
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differentiation. Over the last 10 yr, a growing body of knowl-
edge has emerged regarding the transcriptional control of os-
teoblast differentiation and function. Runx2 is the earliest
determinant of osteoblast differentiation, and its expression
defines a bipotential cell type called an osteochondroprogenitor
(Ducy et al., 1997). Downstream of Runx2, other osteoblast-
specific transcription factors have been identified. One is osterix,
which has mainly been studied in a developmental context until
this point (Nakashima et al., 2002). The other is ATF4, which
controls both osteoblast differentiation and function (Yang et
al., 2004; Elefteriou et al., 2005). We report that p53 negatively
regulates osteoblast differentiation and function by repressing
the expression of osterix. The level of osterix, but not that of
Runx2 or ATF4, was elevated in osteoblasts and the bones of
 
p53
 
 
 
/
 
 
 
 mice, and elevated expression of p53 inhibited osterix
expression and the 
 
Osx
 
 promoter activity in a p53-binding–
independent manner. Moreover, p53 deficiency conferred the
osteoblasts with an increased ability to promote osteoclasto-
genesis, most likely through the up-regulation of macrophage-
colony stimulating factor (M-CSF). This study adds to our
current knowledge of osteoblast differentiation, osteoblast-
supported osteoclastogenesis, bone remodeling, and the devel-
opmental role of the tumor suppressor p53.
 
Results
 
p53
 
 
 
/
 
 
 
 mice showed increased bone mass 
and increased bone formation
 
To determine whether p53 has a role in the skeleton, we ana-
lyzed bones from 3–4-mo-old wild-type and p53
 
 
 
/
 
 
 
 mice. No
evident abnormality was observed in the gross development
of the skeleton. Histological analysis of hematoxylin-eosin–
stained long bone sections indicated that the growth plates
were not significantly altered either (Fig. 1 A). However, dual
x-ray absorptiometry analysis of eight 
 
p53
 
 
 
/
 
 
 
 mice and their
littermate controls revealed that 
 
p53
 
 
 
/
 
 
 
 mice showed a modest
but consistent increase in bone mineral density (Fig. 1 B). von
Kossa staining and bone histomorphometric analysis of the
sectioned long bones revealed that 
 
p53
 
 
 
/
 
 
 
 mice had a 29% in-
crease in the number of trabecular bones and a 40% increase in
the volume of trabecular bones (Fig. 1, C–E). A slight increase
was detected in the volume of cortical bones (45.7 
 
 
 
 2.8%
[bone vol/tissue vol] for 
 
 
 
/
 
 
 
 vs. 52.4 
 
 
 
 2.7% for 
 
 
 
/
 
 
 
 of
femurs, 
 
n
 
 
 
 
 
 8, P 
 
 
 
 0.035). In vivo calcein labeling revealed
that 
 
p53
 
 
 
/
 
 
 
 mice consistently showed a marked increase in the
mineral apposition rate and bone formation rates at the peri-
osteal surface (Fig. 1, F–I), as well as in the trabecular bones
(Fig. 1, J–L), but not at the endosteal surface (not depicted).
Additionally, 
 
p53
 
 
 
/
 
 
 
 mice also showed a marked increase in
the osteoblast surface and the number of osteoblasts per bone
surface (Fig. 1, M and N). Together, these results established
that p53 exerts a negative influence on osteoblast differentia-
tion and/or function.
 
p53
 
 
 
/
 
 
 
 osteoblasts showed increased 
proliferation rates and accelerated 
differentiation
 
In an effort to decipher the cellular mechanisms leading to the
increase in bone mass observed in 
 
p53
 
 
 
/
 
 
 
 mice, we first wanted
to determine whether the bone marrow contains the same
number of osteoprogenitor cells as in control mice. Total bone
marrow cells were counted and directly plated in a 35-mm
plate. The alkaline phosphatase (ALP) colony–forming units
and total colony-forming units were comparable between 
 
p53
 
 
 
/
 
 
 
and control mice (Fig. 2 A), suggesting that p53 deficiency did
not significantly alter the differentiation potential of mesenchymal
cells into osteoblasts.
To attest that p53 negatively regulates osteoblast differ-
entiation, we isolated calvarial primary osteoblasts from wild-
type and 
 
p53
 
 
 
/
 
 
 
 mice. Differentiation assays showed that 
 
p53
 
 
 
/
 
 
 
osteoblasts expressed more ALP (Fig. 2 B), with the p53
heterozygous culture displaying an intermediate phenotype.
Figure 1. Mice deficient for p53 showed increased bone mass and
increased bone formation rates. (A) Normal growth plates in p53
 / 
mice. Femurs were fixed, decalcified, and stained with hematoxylin-
eosin. (B) Bone mineral density (BMD) of the mutant and wild-type
mice of the same age and gender. Femur bones were taken from
3–4-mo-old p53 knockout and control mice and their bone densities
measured (n   8, P   0.004). (C) A representative von Kossa stain-
ing of the femurs of mutant and control mice showing an overall im-
proved trabecular bone in p53
 /  mice. (D) The number of trabecular
bones was increased in p53
 /  mice (n   8, P   0.014). (E) p53
 / 
mice had increased trabecular bones (trabecular bone vol/tissue vol;
n   8, P   0.0037). (F) Calcein labeling of the cortical bones in mu-
tant and control mice. 3–4-mo-old mice were injected with calcein
twice, with an interval of 9 d. The mice were killed and femur bones
sectioned without decalcification. Pictures were taken under a fluores-
cence microscope (40 ). (G) Interlabel width ( m;  n    8, P  
0.025). (H) Mineral apposition rates (n   8, P   0.025). (I) Bone for-
mation per bone perimeter. (n   8, P   0.0004) (J) Mineral apposi-
tion rates in trabecular bones (n   8, P   0.03). (K) Trabecular bone
formation rates per bone perimeter (n   8, P   0.032). (L) Bone for-
mation rate per bone area in trabecular bones (n   8, P   0.032).
(M) p53
 /  mice showed increased osteoblast surface (osteoblast
surface/bone surface; n   5, P   0.012). (N) p53
 /  mice showed
increased osteoblast numbers (osteoblast numbers/bone surface;
n   5, P   0.034). Bar, 500  m. Error bars represent   SD. Asterisks
mark samples significantly different from control with P   0.05. 
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Quantitative assays for ALP (enzyme activities normalized to
total protein levels or the number of osteoblasts) confirmed the
results obtained from histological staining (Fig. 2, C and D).
During the second to third week in culture, osteoblasts start to
express osteocalcin (
 
Bglap1
 
), an osteoblast-specific gene that
is a marker of fully differentiated osteoblasts and is involved in
osteogenesis. Wild-type osteoblasts exhibited a gradual in-
crease in osteocalcin levels over time, whereas p53
 /  osteo-
blasts expressed maximal osteocalcin from day 0 of culture,
suggesting that p53 negatively regulates osteocalcin expression
(Fig. 2 E). Similarly, increased nodule formation or bone min-
eralization was observed in p53 null osteoblast cultures (Fig.
2 F), and reconstitution of p53 by retroviral infection blocked
the accelerated differentiation of p53
 /  osteoblasts and retro-
viral expression of p53 in control cells inhibited their differen-
tiation (Fig. 2, G and H). Enhanced osteoblast differentiation
was also observed in bone marrow stromal cultures of p53
 / 
mice (unpublished data). These results indicate that the bio-
logical function of p53 in cells of the osteoblast lineage is to
inhibit or slow down their differentiation.
To test whether p53 affects proliferation of osteoblasts,
we compared the growth rates of p53
 /  and control osteo-
blasts and found that in the absence of p53 osteoblasts doubled
at a higher rate (Fig. 2 I). This may explain why p53
 /  mice
exhibit an increased number of osteoblasts in vivo. Western
blot analysis revealed that expression of the cyclin-dependent
kinase inhibitor p21was abolished in p53
 /  cells (Fig. 2, J and K).
This may explain why p53 osteoblasts have a shorter cell cycle.
Surprisingly, we found that in p53
 /  cells the levels of p16
ink4
were up-regulated, whereas cyclin-dependent kinase 4 and
cyclin D1 were down-regulated (Fig. 2 , J and K). This may
reflect a compensation mechanism for the loss of p53. To con-
firm that enhanced differentiation is not caused by accelerated
proliferation, we expressed p21 in p53
 /  osteoblasts with a
retrovirus and found that cell proliferation rates were down to
those of control osteoblasts (not depicted), yet these osteoblasts
still exhibited enhanced differentiation (Fig. 2 L), suggesting
that enhanced differentiation caused by p53 deficiency is inde-
pendent of cell proliferation.
Up-regulation of osterix in p53
 /  
osteoblasts and mice
To determine the molecular basis of p53 action in osteoblast,
we next asked whether it could influence expression or func-
tion of the known osteoblast-specific transcription factors such
as Runx2, Osterix, and ATF4. Total RNA was isolated from
p53
 /  and control osteoblasts at different stages of differentia-
tion and used for RT-PCR assays. No dramatic up-regulation of
Runx2 was observed during differentiation of mutant or control
cells. Nor was there a significant difference in the basal levels
of Runx2 or ATF4 between p53
 /  and control osteoblasts
(Fig. 3, A and C; and not depicted). On the other hand, p53
 / 
osteoblasts showed a significant elevation of osterix at the
basal level (Fig. 3 A). In both p53
 /  and control osteoblasts,
Figure 2. Calvarial osteoblasts showed enhanced differ-
entiation. (A) p53 deficiency did not significantly alter the
differentiation potential of mesenchymal cells into osteo-
blasts. Colonies containing  25 cells were counted (per
2.5   10
6 bone marrow cells). (B) Calvarial osteoblasts
were isolated from newborn mice and cultured to pas-
sage 3. The same number of cells was then plated into
12-well plates at 2.5   10
5 per well. (C) Quantitation of
ALP activities of p53
 /  and control wild-type cells that
were normalized to protein levels. (D) Quantitation of ALP
activities of p53
 /  and control wild-type cells that were
normalized to the number of cells. The ALP activity for
control cells at day 1 was set at 1. (E) Northern blot anal-
ysis shows that expression of osteocalcin during differenti-
ation of p53
 /  and control calvarial osteoblasts. The
level of osteocalcin in control osteoblasts at day 0 was set
at 1. (F) Osteoblasts were cultured as in B, except that the
cells were stained using the von Kossa method for min-
eral deposition. (G and H) Reconstitution of p53 led to
normal differentiation of p53
 /  osteoblasts, justified
by ALP staining (G) and quantitative ALP (H). (G, bot-
tom) Expression of p53 in mutant and control cells. (I)
p53
 / osteoblasts showed reduced doubling time. 4  
10
5 cells (triplicates) were plated in 60-mm plates, and
the number of cells were counted every day for 5 d and
plotted. Doubling time was calculated from three p53
 / 
osteoblasts and their control littermates. (J) Expression of
proteins involved in cell proliferation. The experiments
were carried out as described in I, and one plate was
harvested each day for Western blot analysis. (K) Quanti-
tation data (day 3) for the data presented in J. (L) Retroviral
expression of p21 in p53
 /  osteoblasts did not signifi-
cantly repress differentiation. p53
 /  and control osteo-
blasts were infected with p21-expressing retrovirus (or
control retrovirus), selected for 5 d, and plated for ALP
assays. Error bars represent   SD. Asterisks mark samples
significantly different from control with P   0.05.JCB • VOLUME 172 • NUMBER 1 • 2006 118
expression of osterix peaked rapidly at day 2 and subsided to
basal levels later on. Still, p53
 /  osteoblasts displayed a much
higher peak value than control cells. This up-regulation of os-
terix could be a cell response to bone morphogenetic proteins
(BMPs) that are secreted by osteoblasts. The results suggest
that the effect of p53 on osteoblast differentiation is down-
stream of Runx2 and upstream of osterix. Note that p53 levels
started to increase at day 4 during differentiation, and the sig-
nificance of this regulation warrants further investigation (Fig.
3 B). Moreover, we found that osterix, but not other transcrip-
tion factors, was up-regulated in calvarial bones of p53
 /  mice
(Fig. 3, D and E). In situ hybridization using RNA probes gen-
erated from the osterix coding sequence confirmed the results
(Fig. 3 F and not depicted). Overall, these results suggest that
one function of p53 is to inhibit osterix expression and, hence,
osteoblast differentiation.
p53 repressed the promoter activity of 
osterix
Two experiments further support that p53 plays a negative role
in osterix expression. Primary mouse embryonic fibroblasts
(MEFs), when stimulated with BMP2, start to express osteo-
blast-specific markers. We found that osterix was markedly in-
duced in p53
 /  MEFs compared with control cells, in response
to a short-term treatment with BMP2 (Fig. 4 A). Furthermore,
when p53 was up-regulated by the DNA damage reagent cis-
platin it repressed the expression of osterix in wild-type primary
osteoblasts, but not in p53
 /  osteoblasts (Fig. 4 B). These
results confirmed that p53 is a negative regulator of osterix.
To test whether p53 represses the transcription of osterix,
a 6.0-kb DNA fragment upstream of the transcription start site
of osterix gene (Osx) was fused to the luciferase gene in pGL3
basic vector. Coexpression of p53 led to a dosage-dependent
repression of Osx promoter activity in C2C12 and MC3T3-E1
cells (Fig. 4 C and not depicted). p53R273H, a mutant with no
DNA-binding ability, still significantly repressed Osx promoter
(Fig. 4 D), suggesting that DNA binding may not be required.
Moreover, p53S15A, a mutation of a phosphorylation site im-
portant for transactivation of p53 target genes in response to
DNA damage, could repress the Osx promoter. On the other
hand, p53 mutants such as p53 62-91 (the proline-rich domain
deleted), p53M246I (point mutation in the DNA-binding do-
main), and p53L22Q/W23S (two point mutations that abolish
p53 transactivation activity), which were reported to have dra-
matically reduced the ability to repress other p53 target genes
(Murphy et al., 1996; Venot et al., 1998; Roth et al., 2000),
failed to repress the Osx promoter (Fig. 4 D). These results
suggest that p53 might repress Osx promoter activity with a
common mechanism.
The following observations suggest that p53 represses the
Osx promoter independent of DNA binding. First, no canonical
p53-binding site was present in the 6-kb promoter sequence.
Second, serial deletion experiments indicated that all fragments
(6, 4, 2, 1.0, 0.5, 0.3, and 0.13 kb upstream of the start site)
could still be repressed by p53 (Fig. 4 E). This 0.13-kb frag-
ment contains mainly the TATA box–like sequence and is a
minimal sequence that retains some activity in a reporter assay.
Third, chromatin immunoprecipitation assays demonstrated
that p53 was not directly associated with the 2-kb sequence of
the osterix promoter even though its binding was detectable at
the p21 promoter (unpublished data). These results suggest that
p53 repressed osterix transcription independent of its binding
to the upstream activation sequence.
We also found that p300, among several transcription
factors and coactivators, could activate the Osx promoter, and
that this activation was repressed by p53 as well (Fig. 4 F).
Because p300 is expressed in the cells at a limiting concentra-
tion, it is possible that p53 subjugates this coactivator to repress
gene transcription, as proposed previously (Vo and Goodman,
2001; Soussi and Lozano, 2005). To date, p53 has been re-
ported to inhibit the transcription of many genes like Osx.
Yet, the molecular mechanisms behind the repression are not
well understood. This prevents us from establishing the exact
role of p53 in the repression of Osx transcription.
Figure 3. Osteoblasts deficient for p53 showed up-regulated
expression of osterix, but not Runx2. (A) Mutant and control
osteoblasts were collected at different stages of differentiation.
Total RNA was isolated and used for RT-PCR. (B) Expression of
p53 changed during osteoblast differentiation. Cells at different
stages of differentiation were harvested and the levels of p53
were determined by Western blot analysis. (C) Quantitation data
from A and B (similar results were obtained from four pairs of
p53
 /  and control osteoblasts). The level of osterix, Runx2, or
p53 in control osteoblast was set at 1. (D and E) Elevated expres-
sion of osterix mRNA in calvaria of p53
 /  mice. Total RNA was
made from calvaria of p53
 /  and control mice and used for
RT-PCR for osterix, Runx2, and Dlx5 (D), or real-time PCR for
osterix (E) to assess the mRNA levels of osterix. The level of osterix
mRNA in control calvaria was set at 1. The internal control for
real-time PCR was GADPH mRNA. (F) In situ staining of osterix
mRNA. Femurs of p53
 /  and control mice were OCT embedded
and cryosectioned, fixed, and then hybridized with radio-labeled
osterix antisense RNA probe. Osterix is mainly expressed at sites
of mature osteoblasts beneath the growth plates. Bar, 500  m.
Error bars represent   SD. Asterisks mark samples significantly
different from control with P   0.05.P53 REPRESSES BONE REMODELING • WANG ET AL. 119
Elevated osterix mediated the enhanced 
differentiation of p53
 /  osteoblasts
We then attempted to determine whether elevation in osterix
mediated the enhanced differentiation of p53
 /  osteoblasts.
We first tested whether osterix overexpression could lead to
enhanced differentiation. p53
 /  and control osteoblasts were
infected with retroviruses expressing osterix, selected against
puromycin for 3 d, and then used for ALP or osteocalcin assays
(Fig. 5, A–E). We observed a retroviral dose-dependent in-
crease in osterix levels (Fig. 5, B and D), which was likely
caused by multiple infections in a single cell. An up-regulation
in ALP activities and osteocalcin was also seen (Fig. 5, A,
C, and E). When retrovirus-infected wild-type osteoblasts ex-
pressed osterix to the level of p53
 /  osteoblasts, they expressed
similar levels of ALP and osteocalcin as p53
 /  cells (Fig. 5, C
and E). These results indicate that elevation of osterix could
promote osteoblast differentiation and the enhanced differenti-
ation of p53
 /  osteoblasts might be at least partially mediated
by the increased expression of osterix. Second, we attempted to
determine whether increased osterix expression was required
for the enhanced differentiation of p53
 /  osteoblasts. Small
interfering RNA (siRNA)–mediated knocking down of osterix
was performed in control and p53
 /  osteoblasts and osteoblast
differentiation markers were analyzed (Fig. 5, F–J). Different
combinations of siRNA species reduced osterix to different
levels (Fig. 5, G and I), leading to decreased expression of ALP
and osteocalcin (Fig. 5, F–H and J). The results suggested that
osterix was necessary for osteoblast differentiation and that the
effect of p53 on osteoblast differentiation might be at least
partially mediated by osterix.
p53
 /  osteoclasts showed normal 
differentiation and resorption in culture
Increased bone mass could be attributed to reduced bone re-
sorption, in addition to increased bone formation. Further
analysis revealed an unanticipated result. p53
 /  mice showed
a onefold increase in the bone resorption surface and the num-
ber of osteoclasts (Fig. 6, A and B). p53
 /  mice also showed
an increase in the excretion of urine deoxypyridinoline cross-
links (Fig. 6 C). These data indicate that p53
 /  mice have in-
creased bone resorption in addition to increased bone formation.
This may explain why p53
 /  mice only showed modest osteo-
sclerotic phenotypes despite bone formation rates being nearly
double that of control mice.
To determine whether deficiency of p53 has a cell-auton-
omous effect on osteoclasts, we analyzed osteoclastogenesis
and osteoclast resorption of p53
 /  and control bone marrow
monocytes (BMMs) in the presence of M-CSF and receptor ac-
tivator of NF B ligand (RANKL), which are necessary and
sufficient for osteoclast proliferation and differentiation. No
significant difference was observed in the number of osteo-
clasts formed from p53
 /  and control BMMs (Fig. 6, D and E)
nor did we observe a significant difference in the bone resorp-
tion activities of the p53
 /  and control osteoclast cultures
based on pit formation on dentine slices (Fig. 6, F and G).
These results suggest that p53 has no cell-autonomous effect
on the differentiation and the function of osteoclasts.
p53
 /  osteoblasts had increased 
osteoclastogenic capabilities secondary 
to an increase in M-CSF
The aforementioned findings raised the possibility that increased
activities of p53
 /  osteoblasts led to increased osteoclastogenesis
and bone resorption in vivo. It has been well established that
osteoblasts control osteoclast differentiation by synthesizing
M-CSF, RANKL, and osteoprotegerin (OPG, a RANKL decoy
receptor; Suda et al., 1999; Boyle et al., 2003). To prove this,
we cocultured primary calvarial osteoblasts (p53
 /  or control)
Figure 4. p53 inhibited the promoter activity of osterix. (A) Induction of
osterix mRNA by BMP2 in p53
 /  and control MEFs. MEFs were stimu-
lated with 100 ng/ml BMP2 for different periods of time. Total RNA was
isolated, and RT-PCR was performed. Similar results were obtained from
three pairs of mutant and control MEFs. The level of osterix in control cells
at time 0 was set at 1. (B) DNA damage inhibited the expression of osterix.
p53
 /  and control osteoblasts were treated with 5 or 10  M of cisplatin
for 24 h, and total RNA was isolated for RT-PCR assays. (bottom) The values
of the Y axis were normalized to the level of actin, with the basal level of
control cells set at 1. (top) Western blot analysis of p53 induction by
cisplatin in control osteoblasts. *, P   0.05, compared with the same
genotype without CDDP treatment. (C) Coexpression of p53 inhibited the
basal level of the promoter activity in osterix promoter-Luc. (D) Effects of
p53 mutants on osterix promoter activity. Each of these p53 mutant con-
structs was cotransfected into C2C12 cells with the reporter gene, and
luciferase activity was measured. (E) Serial deletion analysis of the osterix
promoter. Different constructs were cotransfected into C2C12 cells with
1  p53 expression construct and the luciferase activities were measured
as in C. The repression was compared with the 6-kb promoter (   ).
(F) p53 repressed Osx promoter activity in the presence of p300. The
experiments were performed as in D, except that TBP or p300 was in-
cluded. 0.3  g DNA was used for each expression construct. Error bars
represent   SD.JCB • VOLUME 172 • NUMBER 1 • 2006 120
with BMMs (p53
 /  or control) in the presence of 10
 8 M di-
hydroxyvitamin D3, and stained for tartrate-resistant acid
phosphatase (TRAP)–positive cells (Fig. 6, H and I). Primary
osteoblasts were plated at a high density so that the plates
would become confluent overnight. This was to eliminate any
possible effects of growth disparity of osteoblasts. These
TRAP-positive osteoclasts were much smaller, compared with
those formed in the presence of M-CSF and RANKL (Fig. 6 D),
with a small multinucleated portion, similar to what has been
observed in previous studies (Geoffroy et al., 2002). Neverthe-
less,  p53
 /  osteoblasts exhibited a marked increase in the
number of TRAP-positive osteoclasts regardless of the geno-
type of BMMs, compared with p53
 /  osteoblasts. When only
cells with  3 nuclei were counted, a 2.5-fold increase was ob-
served for monocytes (both p53
 /  and p53
 / ) cultured on
p53
 /  osteoblasts, compared with those cultured on control
osteoblasts (Fig. 6 J). p53
 /  and p53
 /  monocytes behaved
similarly when cultured on p53
 /  osteoblasts or wild-type os-
teoblasts, confirming that p53 did not have a cell-autonomous
effect on osteoclastogenesis (Fig. 6, D and E). These results
indicated that osteoblasts deficient for p53 had increased po-
tentials in promoting osteoclastogenesis and that the increased
osteoclast number and bone resorption observed in p53
 / 
mice might be attributable to the enhanced activities of p53
 / 
osteoblasts. In accordance with the enhanced osteoclastogene-
sis, RT-PCR analysis revealed a significant increase in the
level of M-CSF in p53
 /  osteoblasts, but not of RANKL or
OPG (Fig. 6 K and not depicted). M-CSF controls both the pro-
liferation and the differentiation of osteoclasts (Tanaka et al.,
1993; Sarma and Flanagan, 1996). Moreover, ectopic expres-
sion of osterix in primary cells was found to increase the level
of M-CSF in a dosage-dependent manner (Fig. 6 L), suggesting
that the enhanced osteoclastogenesis capacity of p53
 /  osteo-
blasts may be attributable to the elevated expression of osterix.
p53 acted downstream of c-Abl in 
osteoblast differentiation
Mice deficient for c-Abl show signs of osteoporosis, and the
mutant osteoblasts show defects in differentiation and survival
against oxidative stress (Li et al., 2000, 2004). Because p53 is a
c-Abl–interacting protein and genetically interacts with c-Abl
during cell proliferation and apoptosis (Whang et al., 2000;
Deng et al., 2004), we studied their relationship in bone devel-
opment. Unfortunately, compound homozygous mice for c-Abl
and p53 were very difficult to obtain, probably owing to the
embryonic and/or postnatal lethality of these mice. Neverthe-
less, we isolated calvarial osteoblasts from four 20-d embryos
of double homozygous mice and control littermates, and com-
pared their differentiation potential. The compound knockout
cells behaved similarly to p53
 /  osteoblasts in ALP expres-
sion and in mineral deposition (Fig. 7, A–C). Real-time PCR
assays indicated that osterix expression was down-regulated in
c-Abl–deficient cells but up-regulated in the compound double
knockout mice, resembling p53
 /  osteoblasts (Fig. 7 D).
These data suggest that p53 functions downstream of c-Abl in
the process of osteoblast differentiation.
Figure 5. Elevated expression of osterix was necessary
and sufficient for accelerated differentiation of p53
 / 
osteoblasts. (A) Ectopic expression of osterix led to in-
creased expression of the osteoblast marker ALP. Wild-
type primary osteoblasts were infected with increasing
amounts of retrovirus expressing osterix, selected for 3 d,
and stained for ALP. (B) Western blot analysis showed
the levels of osterix in cells infected with the retrovirus
(top). RT-PCR assays showed the increase of osteoblast
marker osteocalcin in response to ectopic expression of
osterix (bottom). (C) ALP activities normalized to the level
of proteins. Control cells infected with vector were set at 1.
(D) Quantitation data for the protein levels of osterix in B.
Control cells infected with vector were set at 1. (E) Quan-
titation data for the mRNA levels of osteocalcin in B. Con-
trol cells infected with vector were set at 1. (F) Knocking
down of osterix (a1 to a5) led to a reduction in ALP expres-
sion in p53
 /  osteoblasts. p53
 /  and control osteoblasts
were transfected with siRNA against osterix and control
oligos for 2 d and the plates were stained for ALP. Different
combinations of four commercially designed siRNA spe-
cies were used to obtain different degrees of knocking
down. a1, 1 2 siRNA duplexes; a2, 3 4 duplexes; a3,
1–4 duplexes; a4, 1–4 duplexes (2 ); a5, 1–4 duplexes
(4 ). (G) Western blot analysis showed the levels of osterix
in cells transfected with siRNAs (top). RT-PCR assays
showed the decrease of osteoblast marker osteocalcin in
response to knocking down of osterix (bottom). (H) ALP
activities normalized to the level of proteins. Control cells
transfected with control siRNAs was set at 1. (I) Quantita-
tion data for the protein levels of osterix in H. Control
cells transfected with control siRNAs were set at 1. (J)
Quantitation data for the mRNA levels of osteocalcin in H.
Control cells transfected with control siRNAs were set at 1.
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Discussion
We provide genetic evidence that p53 plays a negative role in
postnatal bone development, with a cell-autonomous effect on
osteoblastogenesis. The mice deficient for p53 displayed in-
creased bone formation and osteosclerotic phenotypes; the os-
teoblasts deficient for p53 showed enhanced proliferation and
accelerated differentiation; and p53 deficiency could overcome
the differentiation defects of c-Abl
 /  osteoblasts. Moreover,
p53 deficiency confers the osteoblasts a greater osteoclastoge-
nic capacity, without directly affecting osteoclast differentia-
tion or resorption. Accordingly, increased bone resorption was
also observed in p53
 /  mice. Thus, the osteosclerotic pheno-
type is a net result of the direct effect of p53 on osteoblast action
combined with an osteoblast-mediated effect on osteoclasts.
This osteoblast-supported osteoclastogenesis might explain
why most of the osteosclerosis models associated with en-
hanced osteoblast function do not exhibit a huge increase in
bone mass (Ducy et al., 1996, 2000; Manolagas and Jilka,
1995; Sabatakos et al., 2000).
The conclusion that p53 plays a negative role in osteoblas-
togenesis is supported by the findings that p53 might directly
regulate the expression of osteocalcin (Schwartz et al., 1999;
Chandar et al., 2000). However, our results are not in agreement
with a recent study stating that p53 did not affect osteoblast dif-
ferentiation and mouse bone formation, although they did show
that p53 deficiency rescued the bone loss induced by mechanical
unloading (Sakai et al., 2002). The discrepancy could be caused
by the genetic background (C57BL/6 in our studies, but not men-
tioned by Sakai et al., 2002) or the age of the mice used (4 mo in
our studies vs. 2 mo in the Sakai study), and warrants further
investigation. Nevertheless, our results obtained from studies on
whole mice, the bones, the cells involved, and the participating
molecules convincingly support a negative role for p53 in osteo-
blastogenesis and bone formation that contributes to the osteo-
sclerotic phenotype observed in p53
 /  mice. We also provided
genetic evidence to support that p53 functionally acts down-
stream of c-Abl in postnatal bone development.
Figure 6. Effects of p53 deficiency on osteoclast differen-
tiation and resorption. (A) p53
 /  mice showed increased
osteoclast surface (osteoclast surface/bone surface). n   8,
P   0.013. (B) p53
 /  mice showed an increase in the
number of osteoclasts per bone surface. n    8, P  
0.002. (C) Urinary deoxypyridinoline (DPD) cross-links ex-
cretion was significantly increased in p53-deficient mice
compared with control mice. (D) Normal osteoclast differ-
entiation from BMMs in p53
 /  mice in the presence of
M-CSF and RANKL. (E) Quantitation data from five p53
 / 
and control littermate mice. (F) Normal bone resorption
rates of p53
 /  osteoclasts. Pit formation assays of p53
 / 
and control osteoblasts (two representative views of differ-
ent magnifications; left, stained with Toluidine blue; right,
stained with Gill’s Hematoxylin Solution). (G) Quantitation
of the resorption area by p53
 /  and control osteoblasts
(n   4). (H) p53
 /  osteoblasts showed a much greater
stimulatory effect on osteoclastogenesis. p53
 /  and
control osteoblasts were first plated, and then the BMMs
isolated from p53
 /  and control mice were plated. They
were cocultured for 6 d in the presence of 10
 8 M of vita-
min D3 and stained for TRAP-positive osteoclasts. (I)
Quantitation data from H (n   4). (J) Number of TRAP-pos-
itive cells per well with  3 nuclei. *, P   0.05, compari-
son between osteoclastogenesis ( /  or  /  mono-
cytes) on  /  and  /  osteoblasts. (K) Up-regulation of
M-CSF in p53
 /  osteoblasts. PT-PCR analysis of the
mRNA levels of M-CSF in p53
 /  and control osteoblasts.
The levels of M-CSF mRNA for control cells were set at 1.
(L) Ectopic expression of osterix increased the expression
of M-CSF. RT-PCR was performed for the sample used in
Fig. 5 A. Error bars represent   SD.
Figure 7. Osteoblasts deficient for both p53 and c-Abl showed advanced
differentiation. Compound knockout and control osteoblasts were isolated
from two litters, plated, and stained for ALP (A), quantitative ALP (B), von
Kossa (C), and for assessment of osterix mRNA levels (D). The level of osterix
of control osteoblasts at day 0 was set at 1. Error bars represent   SD.
Asterisks mark samples significantly different from control with P   0.05.JCB • VOLUME 172 • NUMBER 1 • 2006 122
Our findings indicate that p53 plays a role in osteoblast
differentiation without directly affecting the differentiation of
osteoclasts in a cell-autonomous manner. The significance of
the link between p53 and bone development is underscored by
the recent findings that p53 cooperates with TGF  –BMP path-
ways to positively regulate early development of Xenopus laevis
(Cordenonsi et al., 2003; Takebayashi-Suzuki et al., 2003),
which is in contrast to the negative role for p53 in bone ho-
meostasis. One explanation for the opposite roles of p53 in
relationship to the TGF–BMP pathways could be the timing
of these two events. Mesoderm differentiation occurs at an
early stage when p53 levels are high, whereas osteoblast dif-
ferentiation occurs at a much later stage when p53 levels start
to decline (Almog and Rotter, 1997). The inhibition of osterix
by p53 may provide a mechanism to block bone development
in early embryos.
Several lines of experiments suggest that p53 inhibits os-
teoblast differentiation as a result of repressing the expression
of the lineage-specific transcription factor osterix. First, the in
vivo and in vitro data indicate that osterix, but not other tested
transcription factors, was elevated in the absence of p53. Second,
when p53 was up-regulated, osterix expression was repressed
and osteoblast differentiation was impeded. Third, BMP2-
induced osterix expression was enhanced in the absence of
p53. Fourth, p53
 /  osteoblast differentiation could not be ef-
fectively repressed by c-Abl deficiency, consistent with sus-
tained expression of osterix under this condition. Moreover,
p53 was found to inhibit the promoter activity of osterix,
whereas some mutant forms of p53 failed to do so. Finally, we
found that the osterix levels are an important determinant in os-
teoblast differentiation, as the overexpression of osterix led to
enhanced differentiation and the knocking down of osterix led
to reduced differentiation in p53-deficient osteoblasts. Our
findings might provide the first example in which p53-mediated
gene repression has a physiological impact on postnatal devel-
opment of the mouse. Our results suggest that p53 might do so
by inhibiting osterix promoter activity by the minimal pro-
moter independent of its binding to the upstream activation
sequence. There is an increasing number of genes that are
controlled by the core promoter sequence, including the TATA
box (minimal promoter), and it is also becoming evident that
general transcription factors, such as the thyroxine-binding
protein (TBP) and TATA-binding protein-associated factors,
which are associated to the core promoter sequences, can selec-
tively regulate the transcription of certain genes (Green, 2000;
Hochheimer and Tjian, 2003). Moreover, p53 also forms a com-
plex with p300/cyclic AMP response element–binding protein,
which interacts with the basal transcription machinery (Vo and
Goodman, 2001). Our results suggest that p53 might repress Osx
expression by repressing p300. Still, exactly how p53 regulates
transcription of Osx warrants further investigation.
Our findings indicate that p53 has a cell-autonomous role
in osteoblast differentiation and proliferation. It is also reported
that Li-Fraumeni syndrome patients develop osteosarcoma as a
component tumor and that p53 is mutated in 24 to 42% of
osteosarcoma (Toguchida et al., 1992; Varley, 2003). Osteosar-
coma is usually developed from osteoblasts and is related to
periods in life with rapid bone growth. These observations sug-
gest that p53 plays an important function in bone growth. More
interestingly, osterix has been implicated in osteosarcoma devel-
opment, as osterix is down-regulated in both human and mouse
osteosarcoma cell lines and transfection of osterix into osteosar-
coma cells inhibits their growth (Cao et al., 2005). It will be
interesting to determine whether down-regulation of osterix is
related to the p53 status in osteosarcoma cells. In many tumor
cell lines, p53 is mutated but its expression is greatly up-regulated.
Depending on the nature of the mutations, up-regulated p53 may
repress osterix expression. For example, a hot-spot mutation,
R273H, can still repress osterix promoter activity.
Osterix is an Sp1-like transcription factor that has been
studied in the early development of mouse. It is essential for
osteoblast maturation. Osterix has three Zinc-finger domains
and is able to bind to consensus Sp1-binding sites (Nakashima
et al., 2002). We show that p53 deficiency results in the eleva-
tion of osterix and enhanced osteoblastogenesis. Cell culture
studies confirmed that osterix is sufficient and necessary for
osteoblast differentiation. Our results also suggest that osterix
regulates the expression of M-CSF to control osteoclastogene-
sis. M-CSF actually contains in its promoter an Sp1-binding
site, which mediates the effects of estrogen on M-CSF expres-
sion and osteoclastogenesis (Srivastava et al., 1999). It is
likely that osterix directly controls M-CSF expression. Recent
studies revealed that transcription factors involved in osteo-
blast differentiation also regulate osteoclast differentiation
through controlling RANKL and OPG expression. In differen-
tiated osteoblasts, Wnt pathway and TCF1/4 were found to reg-
ulate the expression of OPG and osteoclast differentiation (Glass
et al., 2005). ATF4, a cyclic AMP response element–related
transcription factor that is essential for osteoblast differentia-
tion and function, also regulates the expression of RANKL
and, subsequently, osteoclast differentiation (Glass et al., 2005).
In summary, p53-deficient mice show an osteosclerotic
phenotype, which is a net result of increased bone formation
and increased bone resorption. p53-deficient osteoblasts ex-
hibit accelerated proliferation, enhanced differentiation, and
increased osteoclastogenic activities. Enhanced differentiation
can be mediated by an elevation of osterix expression, and
improved osteoclastogenesis can be mediated by increased
expression of M-CSF, which is also induced by elevated osterix.
These findings suggest that p53 might control bone remodeling
by modulating expression of osteoblast-specific transcription
factor osterix.
Materials and methods
Mice and cell cultures
Both p53
 /  (The Jackson Laboratory) and c-Abl
 /  mice were crossed to
C57BL/6 six times. Primary osteoblasts were isolated from newborn pups
or 20-d-old embryos, as previously described (Li et al., 2000). The cells
were amplified and frozen for future use. Bone marrow stromal cultures
were extracted from 3–4-mo-old mice. Both calvarial osteoblasts and stro-
mal cells were cultured in  -MEM supplemented with 15% FCS (HyClone).
For osteoblast differentiation, cells were cultured in differentiation medium
( -MEM medium containing 50  g/ml ascorbic acid and 10 mM  –glycerol-
phosphate) and were re-fed every 3 d. MEFs were isolated following a
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Osteoclastogenesis and bone resorption assays
For osteoclast differentiation, the bone marrow of 3–4-mo-old mice was
flushed and the monocyte fraction was isolated by centrifugation on a Ficoll
plus lymphocyte separation medium gradient (ICN Biomedicals), washed,
seeded at 7.5   10
4 cells/well of 96-well plates, and cultured for 7 d in
differentiation medium ( -MEM containing 10% FCS [Invitrogen], 30 ng/ml
M-CSF [R&D Systems], and 50 ng/ml soluble recombinant RANKL [Sigma-
Aldrich]). TRAP staining was performed using an acid phosphatase kit
(Sigma-Aldrich). Osteoclast resorption function was assessed by a pit for-
mation assay on dentine slices (OsteoSite). Monocytes were cultured for
2–3 d in the presence of 30 ng/ml M-CSF and 50 ng/ml of soluble re-
combinant RANKL, counted, and plated onto dentine slices that were pre-
incubated with serum for 2 h. After 7 d, the dentine slices were sonicated
in 0.5 M ammonium hydroxide, stained with either Gill’s Hematoxylin or
Toluidine blue for 2 min, washed with water, and photographed under a
light microscope (Eclipse TE 200; Nikon). The resorbed areas were mea-
sured using a densitometry system and were normalized to the number of
osteoclasts in the well. Urine levels of deoxypyridinoline cross-links were
determined using commercial kits (Quidel Corporation) and were normal-
ized to urine creatinine following the manufacturer’s protocols. For cocul-
ture studies, primary calvarial osteoblasts were plated at 5   10
4 per well
in 24-well plates. Upon confluency, osteoclast progenitors (BMMs; 5  
10
5 per 24 wells) were then plated and the cultures were complemented
with 10
 8 M 1, 25 (OH)2 vitamin D3. Multinucleated cells appeared after
6–10 d and were counted.
Western blot analysis
Cells were lysed in TNEN buffer (50 mM Tris, 150 mM NaCl, 5 mM
EDTA, 0.5% NP-40, and 0.1% Triton X-100) supplemented with 1 mM
NaF, Na2VO3, 1 mM PMSF, and 1  g/ml of aprotonin, leupeptin, and
pepstatin. Protein concentration was determined using an assay (Bio-
Rad Laboratories). Proteins were resolved by SDS-PAGE and transferred
to polyvinylidene difluoride membranes (Millipore). Anti-osterix was
generated by injecting rabbits with a synthesized peptide (Biogenes
GMBH). Anti-p53 and -p19 antibodies were purchased from Onco-
gene Research Products, anti-p21 antibodies were purchased from BD
Biosciences, anti-p16 and -p27 antibodies were obtained from Santa
Cruz Biotechnology, Inc., and anti-actin antibodies were obtained from
Sigma-Aldrich.
Luciferase assay
The osterix promoter (fragments ranging from 0.13 to 6.0 kb from the start
of transcription) was cloned into pGL3 (luciferase basic vector; Promega).
Increasing amounts of p53 expression constructs, the promoter plasmid
(pGL3-Osx-Luc), and renilla plasmid (internal control) were cotransfected
into C2C12 or MC3T3-E1 cells. Cells were harvested 24 h later, washed
with PBS, and lysed with reporter lysis buffer (Promega). TBP, p300, and
p53 are expressed under the control of cytomegalovirus promoter (in
pcDNA3, pXJ, and pCMV, respectively). p53 mutants (gifts from K. Löhr
and M. Dobbelstein, University of Marburg, Marburg, Germany) were de-
scribed previously (Roth et al., 2000). The luciferase activities were mea-
sured following the manufacturer’s procedures and were normalized
against the renilla activity. All transient expressions in this assay were per-
formed in triplicate.
Knocking down and ectopic expression of osterix
For siRNA knocking down experiments, the following siRNA oligomers
(Dharmacon) were used: siGENOME on-target duplex 1, sense: GCC-
AUACGCUGACCUUUCAUU; siGENOME on-target duplex 2, sense:
GGGCACAGCUCGUCUGACUUU; siGENOME on-target duplex 3,
sense: CAACACACCUACUCCUUGGUU; siGENOME on-target duplex 4,
sense: GCAGGCAUCUCACCAGGUCUU. The control siRNA oligomer
used was a nontargeting negative siRNA control pool that was transiently
transfected into primary osteoblasts following the manufacturer’s proce-
dures (Dharmacon). After 3 d, cells were harvested for ALP, osteocalcin,
and Western blot analysis. To express osterix in osteoblasts, a retroviral
vector was constructed with osterix ORF cloned into the pMSCVpuro vec-
tor (BioMed Diagnostics). The viruses were produced by transfecting platE
cells following a standard protocol (Li et al., 2004). Osterix retroviral super-
natant (different dilutions) was then used to infect primary cells, followed by
3-d selection against 5  g/ml of puromycin before being harvested for
Western blot, ALP, and RT-PCR assays. Based on the level of GFP ex-
pressed in the virus, the minimum amount of retroviral supernatant that can
infect  80% of the cells was set at 100%. To express osterix at different
levels, different dilutions (50, 100, 150, and 200%) of retroviral super-
natant were used.
RNA isolation, RT-PCR assay, real-time PCR, and Northern blot
Total mRNA was isolated from osteoblasts or MEF cells growing on 60- or
100-mm dishes using TRIzol reagent (GIBCO BRL) and used for Northern
blot analysis as described (Li et al., 2004). Calvaria from newborn pups
or 20-d-old embryos of p53
 /  and wild-type littermates were isolated
and homogenized in TRIzol. The extracts were frozen at  80 C for 1 d
and thawed for RNA extraction. Total RNA was subjected to DNase
treatment (Ambion) and quantitated. 5  g of total mRNA was reverse
transcribed into complementary DNA (cDNA) using AMV (Roche) re-
verse transcriptase. The total reaction was used in the PCR to assay for
the presence of osterix, Runx2, or actin with the following primers: osterix
(197 bp): forward, 5 -TGAGGAAGAAGCCCATTCAC-3 ; reverse, 5 -
ACTTCTTCTCCCGGGTGTG-3 . Runx2 (113 bp): forward, 5 -TGGCAG-
CACGCTATTAAATC-3 ; reverse, 5 -TCTGCCGCTAGAATTCAAAA-3 .
 -Actin  (104 bp): forward, 5 -AGATGTGGATCAGCAAGCAG-3 ; re-
verse, 5 -GCGCAAGTTAGGTTTTGTCA-3 . PCR was performed for 30
cycles of denaturation (94 C for 30 s), annealing (57 C for 30 s), exten-
sion (72 C for 1 min), and one cycle of final extension (72 C for 10 min),
which was just enough to detect the PCR products of osterix and Runx2.
The detection and quantification of target mRNA was performed
with semiquantitative RT-PCR. The amplification for each mRNA was
performed in the linear range for RT-PCR by optimizing the template
concentration and limiting the amplification cycles to below 30 to ensure
exponential amplification.
In most cases, the results were further confirmed by real-time PCR,
which always gave rise to a larger difference between p53
 /  and con-
trol cells than RT-PCR. cDNAs obtained from osteoblast cells and calvaria
of p53
 /  and wild-type mice were used in the presence of specifically de-
signed osterix primers in a 20- l reaction mix with TaqMan MGB probe
(FAM dye-labeled). The osterix expression levels were normalized by
GADPH as an internal control in real-time PCR analysis according to the
manufacturer’s instructions (Applied Biosystems).
Quantitation of RT-PCR and Western blot results
RT-PCR (negative images of gels) or Western blot results were scanned
with a Molecular Dynamics scanning densitometer. The relative levels of
mRNA or protein of interest were then determined by measuring the inten-
sity of the corresponding bands. All values were averages of cell cultures
isolated from at least three p53
 /  mice and their control littermates and
were normalized to the constitutive expression of the housekeeping genes.
In vitro osteoblast differentiation assay
The assays were performed as previously described (Li et al., 2000).
Primary osteoblasts were plated at a high density so that the plates would
become confluent overnight. This was to eliminate any possible effects of
disparity in osteoblast growth rates. The relative ALP activity is defined as
millimoles of p-nitrophenol phosphate hydrolyzed per minute per milligram
of total protein (units).
In situ hybridization
 -S
35-UTP–labeled single-stranded RNA probes were prepared using an
RNA labeling kit (DakoCytomation) following the manufacturer’s proce-
dure with slight modifications. A 200-bp mouse osterix cDNA fragment
was used to generate antisense and sense probes.
Preparation of specimens
All mice were labeled with 15 mg/kg of calcein subcutaneously (Sigma-
Aldrich) twice in an interval of 9 d before death. The right femur of each
animal was dissected free of soft tissue and used for measurement of
femoral bone density by a dual energy x-ray absorptiometer. The right
tibia was dissected and cut into three equal parts. The right proximal tibia
and tibial shaft were fixed in 70% ethanol solution for 2 d and immersed
in Villanueva Osteochrome Bone Stain (Polysciences, Inc.) for 5 d. The
specimens were dehydrated by sequential changes of ascending concen-
trations of ethanol (70, 95, and 100%) and xylene and embedded in
methyl methacrylate (Eastman Organic Chemicals). Frontal sections of the
proximal tibia were cut at 5  m using a microtome (model RM2155; Leica)
and cross sections of the tibial shaft proximal to the tibiofibular junction
were cut at 40  m using a diamond wire Histo-Saw machine (Delaware
Diamond Knives, Inc.). All sections were coverslipped with Eukitt (Cali-
brated Instruments, Inc.) for static and dynamic histomorphometric analysis.
Bone densitometry
Right femoral bone mineral content (BMC) and bone mineral density
(BMD) were determined using a dual-energy X-ray absorptiometer (model
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resolution mode with line spacing of 0.0254 cm, resolution of 0.0127 cm,
and a collimator of 0.9 cm diam. The bones were placed in a Petri dish.
To simulate soft tissue density surrounding the bones, tap water was
poured around the bones to achieve a depth of 1 cm. Results are given for
BMC and for area; area BMD is calculated as BMC/area. In addition to
results for total femur, the distal and mid-region of the femur were ana-
lyzed as subregions. Coefficients of variation for these measurements in
our laboratory are 0.8, 1.0, and 0.6%, respectively.
Histomorphometric analysis
Histomorphometric parameters of cancellous and cortical bones in the
proximal tibia and tibial shaft were measured with a digitizing morphome-
try system, which consists of an epifluorescent microscope (model BH-2;
Olympus), a color video camera, and a digitizing pad (Numonics 2206)
coupled to an computer (IBM) and a morphometry program OsteoMetrics
(OsteoMetrics, Inc.). Measured parameters in cortical bone included total
tissue area, periosteal perimeter, marrow area, endosteal perimeter, peri-
osteal and endosteal single- and double-labeled perimeters, interlabeled
widths, and intracortical resorption area. They were then used to calculate
the percentage of cortical bone area ([total tissue area   marrow area  
intracortical resorption area]   total tissue area   100%), the percentage
of intracortical porosis ([intracortical resorption area   cortical area]  
100%), and the periosteal and endosteal bone formation rate (BFR; [dou-
ble labeled perimeters   single labeled perimeters   2]   [interlabeled
widths   interval time   periosteal perimeters]) according to the standard
nomenclature.
Measured parameters of cancellous bone included total tissue area,
trabecular bone area and perimeter, single- and double-labeled perime-
ters, and interlabeled widths. They were then used to calculate the per-
centage of cancellous bone volume (trabecular bone area   total tissue
area   100%) and cancellous BFR ([double labeled perimeters   single la-
beled perimeters   2]   interlabeled widths   interval time   trabecular
perimeters). The region of bone measured in all groups is 1–4 mm from
the growth plate in the proximal tibia. All measurements and calculations
were referenced to the standard nomenclature.
Image acquisition
Staining of cell culture plates for ALP or mineralization shown in Figs. 2,
5, and 7 was photographed using a digital camera (model Coolpix 995;
Nikon). Micrographs shown in Fig. 6 were visualized on a microscope
(Eclipse TE200; Nikon) with Plan Fluor objectives (4 , 0.13 NA; 10 ,
0.25 NA; 20 , 0.40 NA; 40 , 0.55 NA) or a dissecting microscope
(model SMZ645; Nikon), which were connected to the previously men-
tioned digital camera. Micrographs shown in Figs. 1 and 3 were visual-
ized and captured as described in the previous section. The images were
acquired and processed using Photoshop 6.01 (Adobe). For Western
blots, Northern blots, and DNA gels, the images were acquired from films
or Kodak papers with a scanner (Canoscan N1240U; Canon) and pro-
cessed using Photoshop 6.01.
Statistical analysis
Each experiment was repeated with three or more mutant and control
mice. Statistical analysis was performed using an unpaired t test (STATISTICA
software; StatSoft, Inc.). P values were provided for all in vivo results.
Significant association was defined when P   0.05 compared with control.
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